高迁移率族蛋白1(high mobility group box-1,HMGB1)是一种含有215个氨基酸残基的核蛋白,几乎存在于所有真核细胞中,参与调节染色体结构、基因转录、DNA复制和修复等多项生理过程,在生长发育过程中发挥着重要作用。越来越多的研究结果显...高迁移率族蛋白1(high mobility group box-1,HMGB1)是一种含有215个氨基酸残基的核蛋白,几乎存在于所有真核细胞中,参与调节染色体结构、基因转录、DNA复制和修复等多项生理过程,在生长发育过程中发挥着重要作用。越来越多的研究结果显示,HMGB1通过多种途径参与细胞凋亡、自噬和炎症反应等多种病理生理过程,从而诱导脑缺血再灌注(cerebral ischemia-reperfusion,CIR)损伤。此外,目前发现存在多种物质能靶向抑制HMGB1的表达,进而发挥抗炎、抗细胞凋亡和抗氧化损伤等作用,但具体作用机制仍需更加深入的研究。进一步挖掘和探索HMGB1在CIR损伤中的具体作用及其相关抑制剂将为CIR损伤的临床治疗提供新的潜在候选策略和思路。因此,本文就HMGB1在CIR损伤过程中的作用及其相关抑制剂的研究进展作一简要综述。展开更多
高迁移率族蛋白B1(high mobility group box-1,HMGB1)是一种广泛表达于真核细胞内的非组蛋白核蛋白,不仅在细胞内起作用,在细胞外也发挥着重要作用,参与多种疾病的病理生理过程,尤其在炎症反应中有着重要的地位。大量研究发现,HMGB1参...高迁移率族蛋白B1(high mobility group box-1,HMGB1)是一种广泛表达于真核细胞内的非组蛋白核蛋白,不仅在细胞内起作用,在细胞外也发挥着重要作用,参与多种疾病的病理生理过程,尤其在炎症反应中有着重要的地位。大量研究发现,HMGB1参与儿童呼吸系统疾病,与疾病的严重程度、预后等密切相关,故本文对HMGB1在儿童呼吸系统疾病中的作用及研究进展做一综述,以期为儿童呼吸系统疾病的诊治提供方向。展开更多
高迁移率族蛋白1(high-mobility group box-1,HMGB1)是新发现的一种"晚期炎症介质",而且高表达于多种肿瘤组织,与其相应受体结合参与调节肿瘤细胞的发生、发展。有研究证实HMGB1的拮抗剂能有效抑制肿瘤细胞的增殖,因而HMGB1...高迁移率族蛋白1(high-mobility group box-1,HMGB1)是新发现的一种"晚期炎症介质",而且高表达于多种肿瘤组织,与其相应受体结合参与调节肿瘤细胞的发生、发展。有研究证实HMGB1的拮抗剂能有效抑制肿瘤细胞的增殖,因而HMGB1有望成为抗肿瘤治疗的一种新的靶分子。展开更多
The pro-inflammation factor high-mobility group box protein 1 （HMGB1） has been implicated in the pathogenesis of asthma. In this study, we used a murine model of chronic asthma to evaluate the effects of HMGB 1 on a...The pro-inflammation factor high-mobility group box protein 1 （HMGB1） has been implicated in the pathogenesis of asthma. In this study, we used a murine model of chronic asthma to evaluate the effects of HMGB 1 on airway remodeling. Female BALB/c mice were randomly divided into four groups： control, ovalbumin （OVA） asthmatic, OVA＋ isotype antibody and OVA＋anti-HMGB 1 antibody. Anti-HMGB 1 antibody therapy was started on day 21 and was administered three times per week for 6 weeks before intranasal challenge with OVA. In this mouse model, HMGB1 expression is significantly elevated. The anti-HMGB1 antibody group exhibited decreased levels of immunoglobulin E （IgE） and inflammatory mediators and reduced inflammatory cell accumulation, airway hyperresponsiveness （AHR）, mucus synthesis, smooth muscle thickness and lung collagen content compared with the OVA groups. Treatment with HMGB1 increased proliferation, migration, collagen secretion and a-smooth muscle actin （SMA） expression in MRC-5 ceils. Treatment with the HMGB1/IL-1β complex significantly increased the expression and secretion of transforming growth factor （TGF-βl）, matrix metalloproteinase （MMP）-9 and vascular endothelial growth factor （VEGF）. Altogether, these results suggest that blocking HMGB1 activity may reverse airway remodeling by suppressing airway inflammation and modulating lung fibroblast phenotype and activation.展开更多
文摘高迁移率族蛋白1(high mobility group box-1,HMGB1)是一种含有215个氨基酸残基的核蛋白,几乎存在于所有真核细胞中,参与调节染色体结构、基因转录、DNA复制和修复等多项生理过程,在生长发育过程中发挥着重要作用。越来越多的研究结果显示,HMGB1通过多种途径参与细胞凋亡、自噬和炎症反应等多种病理生理过程,从而诱导脑缺血再灌注(cerebral ischemia-reperfusion,CIR)损伤。此外,目前发现存在多种物质能靶向抑制HMGB1的表达,进而发挥抗炎、抗细胞凋亡和抗氧化损伤等作用,但具体作用机制仍需更加深入的研究。进一步挖掘和探索HMGB1在CIR损伤中的具体作用及其相关抑制剂将为CIR损伤的临床治疗提供新的潜在候选策略和思路。因此,本文就HMGB1在CIR损伤过程中的作用及其相关抑制剂的研究进展作一简要综述。
文摘高迁移率族蛋白B1(high mobility group box-1,HMGB1)是一种广泛表达于真核细胞内的非组蛋白核蛋白,不仅在细胞内起作用,在细胞外也发挥着重要作用,参与多种疾病的病理生理过程,尤其在炎症反应中有着重要的地位。大量研究发现,HMGB1参与儿童呼吸系统疾病,与疾病的严重程度、预后等密切相关,故本文对HMGB1在儿童呼吸系统疾病中的作用及研究进展做一综述,以期为儿童呼吸系统疾病的诊治提供方向。
基金This study was supported by the Scientific Research and Technological Development Program Project of Guangxi Province （10124001A-32）, the Young Science Foundation of Guangxi Medical University （GXMUSF201206） and the Innovation Project of Guangxi Graduate Education （YCBZ2013014）.
文摘The pro-inflammation factor high-mobility group box protein 1 （HMGB1） has been implicated in the pathogenesis of asthma. In this study, we used a murine model of chronic asthma to evaluate the effects of HMGB 1 on airway remodeling. Female BALB/c mice were randomly divided into four groups： control, ovalbumin （OVA） asthmatic, OVA＋ isotype antibody and OVA＋anti-HMGB 1 antibody. Anti-HMGB 1 antibody therapy was started on day 21 and was administered three times per week for 6 weeks before intranasal challenge with OVA. In this mouse model, HMGB1 expression is significantly elevated. The anti-HMGB1 antibody group exhibited decreased levels of immunoglobulin E （IgE） and inflammatory mediators and reduced inflammatory cell accumulation, airway hyperresponsiveness （AHR）, mucus synthesis, smooth muscle thickness and lung collagen content compared with the OVA groups. Treatment with HMGB1 increased proliferation, migration, collagen secretion and a-smooth muscle actin （SMA） expression in MRC-5 ceils. Treatment with the HMGB1/IL-1β complex significantly increased the expression and secretion of transforming growth factor （TGF-βl）, matrix metalloproteinase （MMP）-9 and vascular endothelial growth factor （VEGF）. Altogether, these results suggest that blocking HMGB1 activity may reverse airway remodeling by suppressing airway inflammation and modulating lung fibroblast phenotype and activation.
